Holen Sie sich die Stockscreener-App
0.5388
7.90%
-0.0462
Vorhandelsmarkt:
.53
-0.0088
-1.63%
Schlusskurs vom Vortag:
$0.585
Offen:
$0.5601
24-Stunden-Volumen:
6.36M
Relative Volume:
8.37
Marktkapitalisierung:
$41.87M
Einnahmen:
$8.23M
Nettoeinkommen (Verlust:
$-32.49M
KGV:
-1.0166
EPS:
-0.53
Netto-Cashflow:
$-19.91M
1W Leistung:
-10.47%
1M Leistung:
-35.08%
6M Leistung:
-42.06%
1J Leistung:
-53.15%
1-Tages-Spanne:
$0.522
$0.58
1-Wochen-Bereich:
$0.292
$0.60
52-Wochen-Spanne:
$0.292
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
Firmenname
Clearside Biomedical Inc
Sektor
Branche
Telefon
678-270-3631
Adresse
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Vergleichen Sie CLSD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.5388 | 45.46M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2025-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-18 | Herabstufung | Stifel | Buy → Hold |
| 2024-08-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-15 | Fortgesetzt | Wedbush | Outperform |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-09 | Herabstufung | Needham | Buy → Hold |
| 2018-11-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2018-11-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-06 | Bestätigt | Needham | Buy |
| 2017-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-10-24 | Bestätigt | Stifel | Buy |
Alle ansehen
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
What drives Clearside Biomedical Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal Delivery - MSN
Clearside Biomedical Announces Approval of XIPERE® - GlobeNewswire
What analysts say about Clearside Biomedical Inc. stockPhenomenal wealth increase - Autocar Professional
Is Clearside Biomedical Inc. a good long term investmentExceptional portfolio growth - Autocar Professional
Clearside Biomedical stock soars after Health Canada approves XIPERE - Investing.com Australia
Clearside Biomedical stock soars after Health Canada approves XIPERE By Investing.com - Investing.com UK
Health Canada approves Clearside’s XIPERE for uveitic macular edema By Investing.com - Investing.com Nigeria
Breakthrough Eye Treatment XIPERE Secures Major Health Canada Approval for Macular Edema - Stock Titan
Clearside Biomedical Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - jammulinksnews.com
Why Clearside Biomedical Inc. stock attracts strong analyst attentionFree Growth Investment Group - Newser
Clearside exploring options to advance suprachoroidal delivery platform - Eyes On Eyecare
Clearside Biomedical announces plan to explore strategic alternatives to advance its proprietary suprachoroidal space (SCS) delivery platform and promising ophthalmology pipeline - Eyes On Eyecare
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Target Price at $4.20 - Defense World
Uncovering the Potential of Clearside Biomedical Inc (CLSD) Stock - investchronicle.com
Clearside Biomedical (NASDAQ:CLSD) Downgraded by Stifel Nicolaus to "Hold" - MarketBeat
Chardan Capital Downgrades Clearside Biomedical (NASDAQ:CLSD) to Neutral - Defense World
What institutions are buying Clearside Biomedical Inc. stock nowFree Stock Trading Signals - beatles.ru
Published on: 2025-07-18 21:44:13 - Newser
Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Health Care Stocks Stumble As Sector Faces Fresh Setbacks - Finimize
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie - Benzinga
Published on: 2025-07-18 22:42:56 - jammulinksnews.com
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
A Quick Look at Today's Ratings for Clearside Biomedical(CLSD.US), With a Forecast Between $0.84 to $3 - 富途牛牛
Clearside Biomedical downgraded to Neutral from Buy at Chardan - TipRanks
This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
CLSD: Downgraded to Neutral by HC Wainwright & Co. | CLSD Stock News - GuruFocus
Why Clearside Biomedical Inc. stock is on top investor watchlistsHigh Return Stock Alerts - Newser
Chardan Capital downgrades Clearside Biomedical stock rating to Neutral By Investing.com - Investing.com Canada
Chardan Capital downgrades Clearside Biomedical stock rating to Neutral - Investing.com
Stifel downgrades Clearside Biomedical stock to Hold on cash concerns By Investing.com - Investing.com Nigeria
Stifel downgrades Clearside Biomedical stock to Hold on cash concerns - Investing.com Australia
Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties - TipRanks
Clearside Biomedical downgraded to Hold from Buy at Stifel - TipRanks
Clearside Biomedical Announces Plan to Explore Strategic - GlobeNewswire
Alpharetta biomedical company ‘exploring strategic alternatives’ as job cuts loom - The Business Journals
Clearside Biomedical shares dip after announcing exploration of strategic alternatives - MSN
Clearside Biomedical to explore strategic alternatives to advance SCS platform - TipRanks
Finanzdaten der Clearside Biomedical Inc-Aktie (CLSD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):